Cholesterol Feeding Prevents Hepatic Accumulation of Bile Acids in Cholic Acid-Fed Farnesoid X Receptor (FXR)-Null Mice: FXR-Independent Suppression of Intestinal Bile Acid Absorption

Masaaki Miyata, Yoshiki Matsuda, Masahiro Nomoto, Yuki Takamatsu, Nozomi Sato, Mayumi Hamatsu, Paul A. Dawson, Frank J. Gonzalez, and Yasushi Yamazoe

Division of Drug Metabolism and Molecular Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, Sendai, Japan (M.M., Y.M., M.N., Y.T., N.S., M.H., Y.Y.); Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, North Carolina (P.A.D.); Laboratory of Metabolism, National Cancer Institute, National Institutes of Health, Bethesda, Maryland (F.J.G.); and CRESCENDO, the Tohoku University 21st Century "Center of Excellence" Program, Sendai, Japan (Y.Y.)

Received May 29, 2008; accepted November 3, 2008

ABSTRACT:

Cholic acid (CA) feeding of farnesoid X receptor (*Fxr*)-null mice results in markedly elevated hepatic bile acid levels and liver injury. In contrast, *Fxr*-null mice fed cholesterol plus CA (CA+Chol) do not exhibit liver injury, and hepatic bile acid levels and bile acid pool size are reduced 51 and 40%, respectively, compared with CA-treated *Fxr*-null mice. These decreases were not observed in wild-type mice. Despite a reduced bile acid pool size, hepatic *Cyp7a1* mRNA expression was increased in *Fxr*-null mice fed the CA+Chol diet, and biliary bile acid output was not changed. Analysis of other potential protective mechanisms revealed significant decreases in portal blood bile acid con-

centrations and a reduced ileal bile acid absorption capacity, as estimated using an in situ loop method. Fecal bile acid excretion was also increased in *Fxr*-null mice fed the CA+Chol versus CA diet. The decreased ileal bile acid absorption correlated with decreased ileal apical sodium-dependent bile salt transporter (ASBT) protein expression in brush-border membranes. These results suggest a critical role for ileal bile acid absorption in regulation of hepatic bile acid levels in *Fxr*-null mice fed CA+Chol. Furthermore, experiments with *Fxr*-null mice suggest that cholesterol feeding can down-regulate ASBT expression through a pathway independent of FXR.

Bile acids are synthesized from cholesterol (Chol) in the liver and play a key role in the intestinal absorption of dietary lipids and fat-soluble vitamins. However, pathophysiological accumulation of bile acids can elicit cytotoxicity, and elevated concentrations are associated with liver injury (Hofmann, 1994). Hepatic bile acid levels are tightly regulated by balancing hepatic uptake, biosynthesis, and efflux (Russell, 2003; Trauner et al., 2005; Pauli-Magnus and Meier, 2006). Hepatic bile acid synthesis and uptake are suppressed, and biliary bile acid excretion is enhanced under conditions of hepatic bile acid accumulation. These functional changes are dependent in part on the hepatic levels of CYP7A1, Na⁺-dependent taurocholate cotransporting polypeptide, and bile salt export pump (Kullak-Ublick et al., 2004; Eloranta et al., 2006; Suchy and Ananthanarayanan, 2006; Norlin and Wikvall, 2007). Hepatic bile acid-activated farnesoid X

receptor (FXR) signaling plays a critical role in these functional changes by directly up-regulating bile salt export pump expression (Ananthanarayanan et al., 2001) and down-regulating CYP7A1 and Na⁺-dependent taurocholate cotransporting polypeptide expression (Goodwin et al., 2000; Lu et al., 2000; Denson et al., 2001).

In the body, more than 95% of bile acids are reabsorbed at the distal ileum and are carried back to the liver. As such, ileal bile acid absorption mediated by transporters, such as apical sodium-dependent bile salt transporter (ASBT) (gene name *Slc10a2*) and organic solute transporter α (OST α)-OST β , is also an important potential factor regulating hepatic bile acid levels (Xu et al., 2000; Dawson et al., 2005; Rao et al., 2008). In some strains of mice, bile acids acting via FXR/small heterodimer partner signaling down-regulate ileal ASBT expression (Chen et al., 2003; Neimark et al., 2004; Li et al., 2005). The ileal uptake of bile acids also plays a critical role in regulating hepatic bile acid content by acting via FXR to induce ileal enterocyte expression of fibroblast growth factor 15 (FGF15). The ileal-derived FGF15 is released into the portal circulation and carried to the liver where it signals to down-regulate CYP7A1 expression (Inagaki et al., 2005). Results confirming a central role for ileal-derived FGF15 in the regulation of hepatic CYP7A1 expression were obtained using the

This study was supported by the Ministry of Education, Science and Culture, Japan [Grants 17390039, 17590114]; the Ministry of Health, Labor and Welfare, Japan [Grant H17-toxico-ippan-001]; and the National Institutes of Health [Grant DK-47987].

Article, publication date, and citation information can be found at <http://dmd.aspetjournals.org>.

doi:10.1124/dmd.108.022590.

ABBREVIATIONS: Chol, cholesterol; FXR, farnesoid X receptor; ASBT, apical sodium-dependent bile salt transporter; OST α , organic solute transporter α ; FGF, fibroblast growth factor; CA, cholic acid; TCA, taurocholic acid; TCDCA, taurochenodeoxycholic acid; DCA, deoxycholic acid; TDCA, taurodeoxycholic acid; HPLC, high-performance liquid chromatography; ALT, alanine aminotransferase; ALP, alkaline phosphatase; BBM, brush-border membrane; PCR, polymerase chain reaction; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; LXR, liver X receptor; PXR, pregnane X receptor.

intestine-specific *Fxr*-null mouse (Kim et al., 2007). Thus, hepatic bile acid levels are coordinately modulated by FXR signaling pathways in both liver and small intestine. Furthermore, signaling via pathways not involving FXR is also likely to contribute to the maintenance of hepatic bile acid levels, although the exact mechanisms remain unclear.

Cholesterol can be directly excreted by the liver into bile or converted into bile acids. Approximately half the biliary and dietary cholesterol is reabsorbed in the proximal small intestine (Altmann et al., 2004) and carried back in chylomicrons to the liver. Intestinal cholesterol absorption is facilitated by forming mixed micelles with bile acids (Woollett et al., 2004, 2006; Hui and Howles, 2005). Thus, the bile acid pool size can affect intestinal cholesterol absorption and hepatic cholesterol catabolism (Ponz de Leon et al., 1981; Dawson et al., 2003). Dietary cholesterol increases the bile acid pool size and fecal bile acid excretion in mice (Tiemann et al., 2004). Thus, it is possible that cholesterol feeding increases hepatic bile acid and cholesterol levels.

Cholic acid (CA) feeding markedly increases hepatic bile acid levels and causes liver injury in *Fxr*-null mice (Sinal et al., 2000), which exhibit impaired regulation of bile acid homeostasis. Hepatic bile acid concentrations are positively correlated with markers of liver injury in *Fxr*-null mice fed a CA diet (Miyata et al., 2005). Hepatic cholesterol levels are also elevated in CA-fed *Fxr*-null mice, raising the possibility that accumulation of hepatic cholesterol contributes to the CA-induced hepatotoxicity in this model. In preliminary studies, the effect of cholesterol coadministration on CA-induced hepatotoxicity was tested in *Fxr*-null mice. We were surprised to find that the addition of cholesterol to the diet ameliorated the hepatotoxicity induced by CA feeding of the *Fxr*-null mice.

To understand the mechanisms underlying the protection against bile acid-induced toxicity in the cholesterol plus CA-fed *Fxr*-null mice, the effects of cholesterol coadministration on bile acid synthesis and transport were investigated. The present study reveals a role for cholesterol-mediated suppression of ileal bile acid absorption as an important FXR-independent mechanism for reducing hepatic bile acid content and bile acid-induced toxicity.

Materials and Methods

Materials. CA, taurocholic acid (TCA), chenodeoxycholic acid, lithocholic acid, tauroolithocholic acid, taurochenodeoxycholic acid (TCDCA), deoxycholic acid (DCA), and taurodeoxycholic acid (TDCA) were purchased from Sigma-Aldrich (St. Louis, MO). β -Muricholic acid, tauro- β -muricholic acid, tauroursodeoxycholic acid, ursodeoxycholic acid, and 5 β -cholanolic acid 3 α , 6 β -diol [internal standard for high-performance liquid chromatography (HPLC) assay] were purchased from Steraloids (Newport, RI). L-Column ODS (2.1 $\times$ 150 mm) was obtained from Chemicals Evaluation and Research Institute, Japan (Tokyo, Japan). Enzymepak 3 α -HSD column was purchased from Jasco (Tokyo, Japan). Monoclonal anti- β -actin antibody (clone AC-15) was purchased from Sigma-Aldrich.

Animal Treatment and Sample Collection. *Fxr*-null (Sinal et al., 2000) and wild-type mice were housed under a standard 12-h light (9:00 AM to 9:00 PM)/12-h dark cycle. Before administration of the special diets, mice were fed standard rodent chow (CE-2; CLEA Japan, Inc., Tokyo, Japan) and water ad libitum. CE-2 originally contains 0.1% cholesterol. The experimental diets used for these studies included standard control diet (CE-2) or control diet supplemented with the following: 0.5% (w/w) CA, 1.25% Chol, 0.5% CA + 1.25% Chol (CA+Chol), and 0.5% CA + 0.5% Chol (CA+Chol 0.5%). Age-matched groups of 8- to 9-week-old male mice were used for all the experiments. Bile, blood, and tissue samples were taken at 9:00 AM for biochemical assays after feeding the special diets for 6 days. In the present study, the short period (6 days) of feeding was chosen because we originally thought that cholesterol coadministration would enhance CA-induced hepatotoxicity in *Fxr*-null mice. Total RNA was prepared from livers and ileum using

the ULTRASPEC II RNA isolation system (Biotecx Laboratories, Inc., Houston, TX). Biliary excretion was monitored in mice anesthetized with ethyl ether. After ligating the common bile duct, bile samples were collected by cannulating the gallbladder using polyethylene tubing (PE-10; internal diameter of 0.28 mm). After a 5-min equilibration period, bile was collected for 30 min. Bile acid pool size was determined as bile acid content of the small intestine, liver, and gallbladder. These tissues were removed and extracted in ethanol as described previously (Schwarz et al., 1998). All of the experiments were performed in accordance with Guidelines for Animal Experiments of Tohoku University.

Plasma Diagnosis Parameters and Plasma, Hepatic, and Biliary Lipid Parameters. Plasma alanine aminotransferase (ALT) and alkaline phosphatase (ALP) activities were measured using commercial kits, Transaminase CII-B-test Wako for ALT and Alkali-phosphatase B-test Wako for ALP (Wako Pure Chemicals, Osaka, Japan). Plasma, hepatic, and biliary total cholesterol concentrations were measured using the cholesterol E-test Wako (Wako Pure Chemicals). Bile acid pool size and hepatic, biliary, and fecal 3 α -hydroxy bile acid concentrations were measured by HPLC as described previously (Kitada et al., 2003; Miyata et al., 2006). The content of β -muricholic acid, tauro- β -muricholic acid, ursodeoxycholic acid, tauroursodeoxycholic acid, CA, TCA, chenodeoxycholic acid, TCDCA, DCA, TDCA, lithocholic acid, and tauro-lithocholic acid was measured.

Ileal Bile Acid Absorption (in Situ Loop Method). The mice were anesthetized with ethyl ether. An ileal loop of approximately 10 cm in length was isolated using ligatures at both ends, and 500 μ l of a dosing solution (5 mM TCDCA in phosphate buffer saline) was injected into the loop with a syringe. The portal blood was collected once from each mouse at 3 or 10 min after the injection.

Western Blot Analysis. Ileal brush-border membranes (BBMs) were prepared as described previously (Kessler et al., 1978). Ileal segments (5 cm) were opened, and the ileal mucosa was obtained by scraping. The ileal mucosa was suspended in 2 mM Tris-HCl, pH 7.1, buffer containing 50 mM mannitol and 0.1 mM phenylmethanesulfonyl fluoride and was homogenized using a Potter homogenizer. After addition of CaCl₂ to a final concentration of 10 mM, the homogenate was incubated on ice for 20 min. The homogenate was centrifuged at 3000g for 15 min, and the supernatant was centrifuged at 27,000g for 30 min. The pellet was suspended in 1 mM Hepes, pH 7.5, buffer containing 100 mM mannitol and 10 μ M MgSO₄.

Ileal BBMs (15 μ g/lane) were subjected to SDS-polyacrylamide gel electrophoresis on 8 or 10% polyacrylamide gels and transferred to nitrocellulose filters. The ileal BBM filters were probed with a polyclonal anti-rodent ASBT antibody (Shneider et al., 1995; Wong et al., 1995) or monoclonal β -actin antibody (Sigma-Aldrich). The filters were washed five times with Tween 20 containing phosphate buffer and incubated with phosphatase-conjugated goat anti-rabbit IgG (1:3000 dilution). Immunoreactive bands were detected using 5-bromo-4-chloro-3-indolylphosphate and nitro blue tetrazolium. The stained membranes were scanned with a Seiko Epson (Suwa, Japan) GT-8700 scanner.

Analysis of mRNA Levels. Hepatic and ileal total RNA were isolated using RNeasy Total RNA Isolation System (Promega, Madison, WI). Single-strand cDNA were synthesized using an oligo(dT) primer and the Ready-to-Go You-Prime First-strand Beads kit (GE Healthcare, Little Chalfont, Buckinghamshire, UK). These cDNA templates were used for real-time polymerase chain reaction (PCR) using SYBR Green 1 with ABI PRISM 7000 Sequence Detection System (Applied Biosystems, Foster City, CA). Quantification was performed by the comparative $\Delta\Delta$ Ct method. The following specific forward and reverse primers were used for real-time quantitative PCR: CYP7A1 sense, 5'-AGCAACTAAACAACCTGCCAGTACTA-3' and antisense, 5'-GTCCG-GATATTCAAGGATGCA-3'; ASBT sense, 5'-TGGGTTTCTTCTGGCTA-GACT-3' and antisense, 5'-TGTTCTGCATTCCAGTTTCCAA-3'; glyceraldehyde-3-phosphate dehydrogenase (GAPDH) sense, 5'-TGTGTCCGTCG-TGGATCTGA-3' and antisense, 5'-CCTGCTTACCACCTTCTTGAT-3'; β -actin sense, 5'-ACCTGTGCTGCTACCGA-3' and antisense, 5'-CTG-GATGGCTACGTACATGGCT; OST α sense, 5'-GCCAGGCAGGACT-CATATCAAA-3' and antisense, 5'-GGCAACTGAGCCAGTGGTAAGA-3'; and ileal bile acid binding protein sense, 5'-AGATCATCACAGA-GGTCCAGC-3' and antisense, 5'-GGTAGCCTTGAACCTTCTTGCC-3'.

Statistical Analysis. All of the values are expressed as the mean $\pm$ S.D. Data were analyzed by unpaired Student's *t* test or by analysis of variance

TABLE 1

Changes in bile acid and cholesterol levels and liver damage diagnostic markers

The data are shown as the mean $\pm$ S.D. from four to six mice. *Fxr*-null and wild-type mice were fed a control diet (Cont) or the diet containing 1.25% Chol, 0.5% CA, or 0.5% CA and 1.25% Chol (CA+Chol) for 6 days.

	Wild-Type				<i>Fxr</i> -Null			
	Cont	Chol	CA	CA+Chol	Cont	Chol	CA	CA+Chol
Liver bile acid (nmol/g liver)	157 $\pm$ 42	72 $\pm$ 68	424 $\pm$ 98 ^a	490 $\pm$ 38 ^a	580 $\pm$ 350	485 $\pm$ 305	2687 $\pm$ 646 ^a	1313 $\pm$ 374 ^{a,b}
Liver cholesterol (mg/g liver)	2.72 $\pm$ 0.32	2.66 $\pm$ 0.46	3.86 $\pm$ 0.95	9.10 $\pm$ 2.16 ^{a,b}	2.83 $\pm$ 0.41	6.14 $\pm$ 0.71 ^a	4.97 $\pm$ 0.90 ^a	14.1 $\pm$ 5.10 ^{a,b}
Plasma cholesterol (mg/dl)	75 $\pm$ 5	57 $\pm$ 6	69 $\pm$ 18	58 $\pm$ 20	111 $\pm$ 9	97 $\pm$ 14	110 $\pm$ 14	160 $\pm$ 16 ^{a,b}
ALT (IU/l)	8 $\pm$ 1	12 $\pm$ 2	103 $\pm$ 53 ^a	183 $\pm$ 63 ^a	38 $\pm$ 7	30 $\pm$ 15	509 $\pm$ 159 ^a	103 $\pm$ 63 ^{a,b}
ALP (IU/l)	29 $\pm$ 4	30 $\pm$ 5	40 $\pm$ 9	33 $\pm$ 10	60 $\pm$ 11	52 $\pm$ 2	602 $\pm$ 103 ^a	291 $\pm$ 60 ^{a,b}

^a $p < 0.05$ versus control group.

^b $p < 0.05$ versus CA group.

followed by Tukey's multiple comparison test using GraphPad Software Inc. (San Diego, CA) Prism 4 for significant differences between the mean values of each group. Probability values of less than 0.05 were considered to be statistically significant.

Results

Liver Damage Diagnostic Markers and Bile Acid Content in CA and/or Cholesterol-Fed Mice. Feeding CA resulted in elevated hepatic bile acid levels, and plasma ALT but not ALP activities were slightly increased in wild-type mice fed the CA or CA+Chol diets (Table 1), with levels less than 200 IU/l. However, there was no significant difference between wild-type mice fed the CA and CA+Chol diets with regard to plasma ALT or hepatic bile acid content. In contrast to wild-type mice, the CA-fed *Fxr*-null mice had markedly elevated plasma ALT and ALP activities (13.5- and 10.0-fold, respectively, relative to the control diet) (Table 1). Plasma ALT and ALP activities were also elevated in *Fxr*-null mice fed the CA+Chol diet; however, the increases were significantly blunted compared with the CA-fed *Fxr*-null (20 and 48% of the CA diet levels, respectively). The hepatic bile acid content was also markedly increased in *Fxr*-null mice fed the CA diet (4.6-fold relative to the control diet) (Table 1). However, as with the liver damage diagnostic markers, feeding CA+Chol diet significantly blunted the increase in hepatic bile acid levels; in the *Fxr*-null mice fed CA+Chol, hepatic bile acid content was decreased 51% compared with the CA-fed *Fxr*-null mice. Significant increases in hepatic cholesterol levels were observed in *Fxr*-null mice fed the Chol, CA, and CA+Chol diets and in wild-type mice fed the CA+Chol diet (Table 1). In contrast to liver, plasma cholesterol levels were significantly increased only in *Fxr*-null mice fed the CA+Chol diet. The effect of cholesterol on CA-induced toxicity and hepatic bile acid content was further examined in *Fxr*-null mice fed diets containing CA and increasing amounts (0, 0.5, and 1.25%) of cholesterol. Feeding increasing amounts of dietary cholesterol plus CA to *Fxr*-null mice reversed the elevation of hepatic bile acid content and plasma ALT and ALP activities in a dose-dependent manner (Fig. 1, A and B). An inverse relationship was found between hepatic content of bile acids and cholesterol (Fig. 1C).

Influence of Cholesterol on Bile Acid Pool Size. To determine whether the decreased hepatic bile acid levels in *Fxr*-null mice fed the CA+Chol diet is reflected in whole-body bile acid levels, bile acid pool sizes were also measured (Table 2). There were no significant differences in bile acid pool size and composition between wild-type mice fed the CA and CA+Chol diets. Despite significantly higher hepatic levels of bile acids in the CA-fed *Fxr*-null mice compared with CA-fed wild-type mice, the total bile acid pool tended to be lower in the *Fxr*-null mice. Thus, ratio of the hepatic bile acid content to total bile acid pool size in *Fxr*-null mice fed a CA diet was 6.5 times higher than that in wild-type mice. However, consistent with changes

FIG. 1. Dose-dependent effect of cholesterol feeding on liver injury diagnostic markers, hepatic bile acid, and cholesterol levels in *Fxr*-null mice. A, plasma ALT activity. B, plasma ALP activity. C, hepatic bile acid (black bar) and cholesterol (white bar) levels. *Fxr*-null mice were fed a diet supplemented with 0.5% CA, 0.5% CA and 0.5% Chol (CA+Chol 0.5%), or 0.5% CA and 1.25% Chol (CA+Chol 1.25%) for 6 days. Data are shown as the mean $\pm$ S.D. ($n = 4$). The data are representative of two independent experiments. *, $p < 0.05$, **, $p < 0.01$, and ***, $p < 0.001$ versus CA diet group.

in hepatic bile acid levels, the bile acid pool size in CA+Chol diet-fed *Fxr*-null mice was decreased 40% compared with CA-fed *Fxr*-null mice. Analysis of the bile acid pool's composition revealed a significant decrease in total CA (TCA + CA) contents in *Fxr*-null mice fed the CA+Chol diet versus CA diet (Table 2). Significant decreases in total DCA (TDCA + DCA) contents were observed in *Fxr*-null mice compared with wild-type mice.

Hepatic Bile Acid Synthesis and Secretion in *Fxr*-Null Mice Fed CA and/or Cholesterol. Cholesterol feeding may protect the liver from bile acid accumulation by inducing hepatic bile acid secretion. Initially, the hepatic expression of CYP7A1 was examined in *Fxr*-null and wild-type mice fed the control, CA, and CA+Chol diets. CYP7A1 mRNA levels were significantly lower in *Fxr*-null and wild-type mice fed the CA diet compared with the control diet (Fig. 2), whereas CYP7A1 mRNA expression was significantly higher in those mice fed the CA+Chol diet compared with the CA diet. To determine the influence of cholesterol coadministration on biliary bile acid excretion in *Fxr*-null mice fed the CA diet, biliary bile acid output rates were determined. No differences in biliary bile acid

TABLE 2

Bile acid composition of bile acid pool

Fxr-null and wild-type mice were fed a control diet containing 0.5% CA or 0.5% CA and 1.25% Chol (CA+Chol) for 6 days. Liver, gallbladder, and small intestine were isolated, and bile acids were extracted. Bile acid pool size was analyzed by HPLC. The data are shown as the mean $\pm$ S.D. from five mice. TLCA, LCA, β MCA, UDCA, TCDCA, and CDCA were below detection limits (0.1 μ mol/100 g b.wt.).

	TCA + CA	TDCA + DCA	T β MCA + β MCA	TUDCA + UDCA	Total
	μ mol/100 g b.wt.	μ mol/100 g b.wt.	μ mol/100 g b.wt.	μ mol/100 g b.wt.	μ mol/100 g b.wt.
Wild-type (CA)	95.9 $\pm$ 11.0	27.9 $\pm$ 16.0	1.1 $\pm$ 1.5	4.0 $\pm$ 2.9	128.9 $\pm$ 15.1
Wild-type (CA+Chol)	79.7 $\pm$ 12.8	29.7 $\pm$ 4.9	0.3 $\pm$ 0.5	4.1 $\pm$ 1.4	113.9 $\pm$ 13.3
<i>Fxr</i> -null (CA)	96.4 $\pm$ 26.1	6.1 $\pm$ 3.4	1.3 $\pm$ 1.0	5.8 $\pm$ 1.8	109.6 $\pm$ 26.2
<i>Fxr</i> -null (CA+Chol)	55.5 $\pm$ 12.6 ^a	5.8 $\pm$ 2.8	0.2 $\pm$ 0.2	3.9 $\pm$ 1.8	65.4 $\pm$ 16.6 ^a

^a $p < 0.05$ versus corresponding CA group.

FIG. 2. Hepatic levels of CYP7A1 mRNA. Hepatic CYP7A1 mRNA levels were measured by real-time quantitative PCR. Hepatic RNAs were prepared from *Fxr*-null and the wild-type mice fed a control diet (Cont) or diet supplemented with 0.5% CA or 0.5% CA and 1.25% Chol (CA+Chol) for 6 days. The mRNA expression levels were normalized to GAPDH mRNA. Ct values for CYP7A1 and GAPDH of wild-type mice fed control diet were 29.1 and 22.0, respectively. Data are shown as the mean $\pm$ S.D. ($n = 4$). The data are representative of two independent experiments. *, $p < 0.05$ and ***, $p < 0.001$ versus control diet group. #, $p < 0.05$ versus CA diet group.

output rates were observed between *Fxr*-null mice fed the control, CA, and CA+Chol diets (Fig. 3).

Ileal Absorption and Fecal Excretion of Bile Acids. Another potential mechanism for protecting the liver from dietary CA-induced bile acid accumulation is reduced intestinal absorption. To estimate ileal bile acid absorption capacity, bile acid concentrations of portal blood were measured in *Fxr*-null and wild-type mice fed the control, CA, Chol, or CA+Chol diets for 6 days. The portal blood bile acid concentration was approximately 11-fold higher in *Fxr*-null mice fed the CA diet compared with *Fxr*-null mice fed the control diet (Fig. 4). The portal blood bile acid concentration in *Fxr*-null mice fed the CA+Chol diet was reduced $\sim$ 70% compared with the CA diet-fed group. In wild-type mice, no significant differences in the portal blood bile acid concentrations were observed between CA diet and CA+Chol diet.

Next, the ileal bile acid absorption was measured using the in situ loop method. TCDCA is efficiently transported by the mouse ASBT but is not typically a component of the mouse bile acid pool. TCDCA concentrations in portal blood were measured after TCDCA was infused into an in situ ileal loop taken from *Fxr*-null and wild-type mice fed the control, Chol, CA, or CA+Chol diets for 6 days. TCDCA concentrations in the portal blood depend on the time after TCDCA injection. The ileal bile acid absorption rate was estimated as TCDCA concentration of portal blood at 10 min after the injection in the following experiments. The ileal bile acid absorption rate was significantly higher in *Fxr*-null mice than

FIG. 3. Changes in biliary bile acid excretion in *Fxr*-null mice. *Fxr*-null mice were fed a control diet (Cont) or diet supplemented with 0.5% CA or 0.5% CA and 1.25% Chol (CA+Chol) for 6 days. Bile was collected for 30 min by bile duct cannulation. Data are shown as the mean $\pm$ S.D. ($n = 5$). The data are representative of two independent experiments.

FIG. 4. Portal blood bile acid levels. *Fxr*-null and wild-type mice were fed a control diet (Cont) or diet supplemented with 1.25% Chol, 0.5% CA, or 0.5% CA and 1.25% Chol (CA+Chol) for 6 days. Portal blood was collected from mice anesthetized with ethyl ether. Bile acid concentration was measured by HPLC as described under *Materials and Methods*. Data are shown as the mean $\pm$ S.D. ($n = 3$). The data are representative of two independent experiments. *, $p < 0.05$ and **, $p < 0.01$ versus control diet group. #, $p < 0.05$ versus CA diet group.

that in the wild-type mice. The rate was reduced to 49% of control in the wild-type mice fed the CA diet (Fig. 5A). No significant changes in the rates were found in *Fxr*-null mice fed the control diet, Chol diet, and CA diet. The rate in *Fxr*-null mice fed the CA+Chol diet was reduced to 38% of the mice fed the CA diet. The rates did not differ in the wild-type mice fed the CA diet and the CA+Chol diet. To confirm the differences in the influence of cholesterol coadministration on ileal bile acid absorption rates between *Fxr*-null and wild-type mice, the ileal bile acid absorption rate was also estimated as TCDCA concentration of portal blood at 3 min after the injection. Consistent with the results of TCDCA concentration at 10 min after injection, the concentrations at 3 min after injection were significantly lower in *Fxr*-null mice fed the CA+Chol diet compared with CA diet-fed *Fxr*-null mice (Fig. 5B). In wild-type mice, no signif-

FIG. 5. Changes in ileal bile acid absorption rate. *Fxr*-null and wild-type mice were fed a control diet (Cont) or the diet supplemented with 1.25% Chol, 0.5% CA, or 0.5% CA and 1.25% Chol (CA+Chol) for 6 days. Portal blood was collected at 10 min (A) or 3 min (B) after TCDCDA injection. Data are shown as the mean $\pm$ S.D. ($n = 5$). The data are representative of two independent experiments. *, $p < 0.05$ and **, $p < 0.01$ versus control group. ##, $p < 0.01$ versus CA group.

icant differences in the concentration were observed between CA diet and CA+Chol diet. These results suggest that cholesterol coadministration decreases ileal bile acid absorption capacity in *Fxr*-null mice fed the CA diet but not the wild-type mice.

Fecal bile acid excretions in *Fxr*-null mice fed the control, CA, and CA+Chol diets were 9.4 ± 1.1 , 14.2 ± 3.2 , and 55.7 ± 15.5 $\mu\text{mol/day/100 g b.wt.}$ (mean $\pm$ S.D.; $n = 5$), respectively. The fecal bile acid excretion was significantly increased in *Fxr*-null mice fed CA and CA+Chol diets compared with *Fxr*-null mice fed the control diet. Furthermore, concomitant with decreases in ileal bile acid absorption, fecal bile acid excretion was significantly increased in *Fxr*-null mice fed the CA+Chol versus CA diet. In wild-type mice, no significant differences in fecal bile acid excretion were observed between CA diet (50.2 ± 7.5 $\mu\text{mol/day/100 g b.wt.}$) and CA+Chol diet (52.1 ± 4.5 $\mu\text{mol/day/100 g b.wt.}$).

Ileal ASBT Protein and mRNA Levels. To identify the mechanisms responsible for reduced ileal bile acid absorption in *Fxr*-null mice fed the CA+Chol diet, the expression of ASBT protein in ileal BBMs was analyzed by Western blot analysis. Proteins recognized by Asbt antibody were higher in ileal BBMs than those in duodenum BBMs from wild-type mice fed CA diet (data not shown). Marked decreases in the contents were found in both wild-type and *Fxr*-null mice fed the CA+Chol diet compared with those mice fed the CA diet (Fig. 6A). Ileal ASBT mRNA levels were not significantly lower in *Fxr*-null and wild-type mice fed CA+Chol diet compared with those mice fed CA diet (Fig. 6B), although marked differences in the protein contents were observed. Similar levels of ileal bile acid binding

FIG. 6. Changes in ileal ASBT protein and mRNA levels. A, ileal ASBT protein level. Ileal BBMs were isolated from wild-type and *Fxr*-null mice fed a control diet supplemented with 0.5% CA or 0.5% CA and 1.25% Chol (CA+Chol) for 6 days. Pooled BBM extracts (15 μg) from four mice were subjected to immunoblot analysis using a polyclonal anti-rodent Asbt antibody or monoclonal anti- β -actin antibody. B, ileal ASBT mRNA level. Total RNA was isolated from ileum of wild-type and *Fxr*-null mice fed a control diet supplemented with 0.5% CA or 0.5% CA and 1.25% Chol (CA+Chol) for 6 days. ASBT mRNA levels were evaluated by real-time quantitative PCR. The mRNA expression was normalized to β -actin mRNA. Ct values for ASBT and β -actin of wild-type mice fed CA diet were 21.5 and 15.5, respectively. Data are shown as the mean $\pm$ S.D. ($n = 4$). The data are representative of two independent experiments.

protein and OST α mRNAs were observed between *Fxr*-null mice fed the CA diet and CA+Chol diet (data not shown).

Discussion

The present study revealed that cholesterol coadministration decreases bile acid pool size and hepatic bile acid concentrations in CA-fed *Fxr*-null mice. Among the potential mechanisms responsible for the effects of cholesterol coadministration are decreased hepatic bile acid synthesis and decreased intestinal absorption. However, mRNA expression for CYP7A1, the rate-limiting enzyme for hepatic bile acid synthesis was significantly increased in *Fxr*-null mice fed the CA+Chol diet compared with the CA diet. In contrast, several lines of evidence suggest that ileal bile acid absorption is decreased in *Fxr*-null mice fed the CA+Chol diet. This includes the findings that the portal blood bile acid concentration was significantly decreased, ileal bile acid absorption was significantly reduced as measured using an in situ loop model, and fecal bile acid excretion was increased. Thus, ileal bile acid absorption is probably responsible in part for the reduced bile acid hepatic accumulation and bile acid pool size in CA+Chol-fed *Fxr*-null mice.

Changes in the ileal BBM content of ASBT protein correlated with ileal bile acid absorption rates in *Fxr*-null but not wild-type mice fed the CA and CA+Chol diets. ASBT-mediated uptake across the BBM is thought to be one of the rate-limiting steps in bile acid transport from the gut lumen into the portal circulation. As such, in *Fxr*-null mice, the reduced ileal ASBT protein expression probably accounts for the decreased ileal bile acid absorption capacity under the condi-

tions of bile acid and cholesterol feeding, although other mechanisms for the reduction of ileal bile acid absorption cannot be excluded. Previous studies have shown that the bile acid pool size is decreased in *Asbt*-null mice or ASBT inhibitor-treated rabbits, despite increased CYP7A1 expression (Dawson et al., 2003; Li et al., 2004). In contrast, cholesterol-fed rabbits exhibit increased ileal ASBT expression and an increased bile acid pool size, despite reduced cholesterol 7 α -hydroxylase activity (Xu et al., 2000). These reports support the hypothesis that ileal ASBT protein expression is at least partially responsible for controlling the bile acid pool size and hepatic bile acid levels in *Fxr*-null mice fed CA+Chol.

Previous studies have reported that feeding a diet containing 2% cholesterol to C57BL/6J mice for 14 days decreased ileal expression of ASBT protein and mRNA (Thomas et al., 2006). The present results found a similar decrease in ASBT protein expression in *Fxr*-null and wild-type mice fed cholesterol in addition to CA. However, the decrease in ileal ASBT mRNA expression in *Fxr*-null and wild-type mice fed the CA+Chol diet was not significant in the present study. The differences in regulation of ASBT mRNA expression between the two studies may reflect the inclusion of CA and different amounts of cholesterol (0.02 versus 0.1% in the control diet and 2 versus 1.25% in the cholesterol supplement diet) and the length of feeding (14 versus 6 days). Although long-term cholesterol feeding might be necessary for the cholesterol-mediated reduction of ileal ASBT mRNA level in mice, the present studies were limited to 6 days because of increased toxicity after this time. Marked decrease (more than 30%) in body weight and severe physical debilitation were observed in some of *Fxr*-null mice fed CA diet for 10 days. It should be noted that both studies found that the decreases in ileal ASBT protein expression was greater than the change in ASBT mRNA expression. These results raise the possibility that cholesterol can down-regulate ASBT protein expression in the ileal BBM by post-translational mechanisms such as protein stability or membrane translocation. Post-translational regulation of ASBT has previously been reported. For example, it has been shown in tissue culture cells that interleukin-1 β can down-regulate ASBT expression by inducing the ubiquitinylation and proteasomal degradation of ASBT protein (Xia et al., 2004). Very recently, it was shown that ASBT protein is localized in cholesterol-containing rafts, and modulation of the cholesterol content regulated ASBT activity. However, in those studies, depletion of membrane cholesterol by using methyl- β -cyclodextrin inhibited ASBT activity in tissue culture cells (Annaba et al., 2008). Although our studies indicate that FXR is not required for this cholesterol regulation of ASBT protein expression, the underlying mechanisms responsible remain to be identified. It has been reported that human ASBT expression is directly down-regulated by 25-hydroxycholesterol (Alrefai et al., 2005). The suppressive effect of cholesterol and 25-hydroxycholesterol on ASBT expression is mediated through sterol regulatory element binding protein 2 and hepatic nuclear factor 1 α in Caco-2 cells (Thomas et al., 2006). ASBT expression is probably down-regulated at least by two distinct mechanisms: cholesterol signaling (sterol regulatory element binding protein) and bile acid signaling (FXR/small heterodimer partner). Cholesterol-mediated signaling seems to play a crucial role in the down-regulation of ileal ASBT expression under the conditions of lacking negative feedback regulation by FXR signaling such as found in the *Fxr*-null mice. The cholesterol-mediated suppression of ileal ASBT expression might be a second defense system against hepatic bile acid accumulation.

Cholesterol metabolites and intermediates in the bile acid biosynthetic pathway can activate liver X receptor (LXR) and pregnane X receptor (PXR) (Goodwin et al., 2003; Sonoda et al., 2005). Feeding the 1.25% cholesterol-containing diet might lead to an accumulation

of these intermediates, which activate LXR and PXR. Under conditions of absence of FXR, activated LXR and PXR might suppress hepatic bile acid accumulation to protect liver against CA-induced injury (Guo et al., 2003; Teng and Piquette-Miller, 2007).

No significant differences in bile acid pool size were observed between *Fxr*-null and wild-type mice fed a CA diet, whereas marked differences in hepatic bile acid content were found. These results raise a possibility that under the CA feeding condition, FXR signaling plays a crucial role in the suppression of accumulating hepatic bile acid content but not that of bile acid pool size. On the other hand, cholesterol-mediated signaling is probably involved in the suppression of accumulating bile acid pool size and hepatic bile acid content under the high bile acid condition of lacking FXR.

In the present study, we showed that cholesterol feeding prevents hepatic bile acid accumulation in CA-fed *Fxr*-null mice via down-regulation of ileal bile acid absorption. Furthermore, using *Fxr*-null mice cotreated with cholesterol and CA, we showed a crucial role of ileal bile acid absorption in regulation of hepatic bile acid levels. Because CA-fed *Fxr*-null mice markedly increase hepatic bile acid levels, the mice seem to be a good model to identify bile acid regulatory mechanisms independent of FXR signaling. The cholesterol-mediated negative regulation of ileal bile acid absorption may be involved in the maintenance of not only bile acid but also cholesterol homeostasis. Further studies are necessary to identify the mechanism for the suppression of ileal bile acid absorption through cholesterol signaling.

Acknowledgments. We thank Miwa Watanabe for skillful technical assistance.

References

- Alrefai WA, Sarwar Z, Tyagi S, Saksena S, Dudeja PK, and Gill RK (2005) Cholesterol modulates human intestinal sodium-dependent bile acid transporter. *Am J Physiol Gastrointest Liver Physiol* **288**:G978–G985.
- Altman SW, Davis HR Jr, Zhu LJ, Yao X, Hoos LM, Tetzloff G, Iyer SP, Maguire M, Golovko A, Zeng M, et al. (2004) Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. *Science* **303**:1201–1204.
- Ananthanarayanan M, Balasubramanian N, Makishima M, Mangelsdorf DJ, and Suchy FJ (2001) Human bile salt export pump promoter is transactivated by the farnesoid X receptor/bile acid receptor. *J Biol Chem* **276**:28857–28865.
- Annaba F, Sarwar Z, Kumar P, Saksena S, Turner JR, Dudeja PK, Gill RK, and Alrefai WA (2008) Modulation of ileal bile acid transporter (ASBT) activity by depletion of plasma membrane cholesterol: association with lipid rafts. *Am J Physiol Gastrointest Liver Physiol* **294**:G489–G497.
- Chen F, Ma L, Dawson PA, Sinal CJ, Sehaye E, Gonzalez FJ, Breslow J, Ananthanarayanan M, and Schneider BL (2003) Liver receptor homologue-1 mediates species- and cell line-specific bile acid-dependent negative feedback regulation of the apical sodium-dependent bile acid transporter. *J Biol Chem* **278**:19909–19916.
- Dawson PA, Haywood J, Craddock AL, Wilson M, Tietjen M, Kluckman K, Maeda N, and Parks JS (2003) Targeted deletion of the ileal bile acid transporter eliminates enterohepatic cycling of bile acids in mice. *J Biol Chem* **278**:33920–33927.
- Dawson PA, Hubbert M, Haywood J, Craddock AL, Zerangue N, Christian WV, and Ballatori N (2005) The heteromeric organic solute transporter α - β , Ost α -Ost β , is an ileal basolateral bile acid transporter. *J Biol Chem* **280**:6960–6968.
- Denson LA, Sturm E, Echevarria W, Zimmerman TL, Makishima M, Mangelsdorf DJ, and Karpen SJ (2001) The orphan nuclear receptor, shp, mediates bile acid-induced inhibition of the rat bile acid transporter, ntcp. *Gastroenterology* **121**:140–147.
- Eloranta JJ, Jung D, and Kullak-Ublick GA (2006) The human Na⁺-taurocholate cotransporting polypeptide gene is activated by glucocorticoid receptor and peroxisome proliferator-activated receptor- γ coactivator-1 α , and suppressed by bile acids via a small heterodimer partner-dependent mechanism. *Mol Endocrinol* **20**:65–79.
- Goodwin B, Gauthier KC, Umetani M, Watson MA, Lochansky MI, Collins JL, Leitersdorf E, Mangelsdorf DJ, Klierer SA, and Repa JJ (2003) Identification of bile acid precursors as endogenous ligands for the nuclear xenobiotic pregnane X receptor. *Proc Natl Acad Sci U S A* **100**:223–228.
- Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, et al. (2000) A regulatory cascade of the nuclear receptors FXR, SHP-1, and LXR-1 represses bile acid biosynthesis. *Mol Cell* **6**:517–526.
- Guo GL, Lambert G, Negishi M, Ward JM, Brewer HB Jr, Klierer SA, Gonzalez FJ, and Sinal CJ (2003) Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity. *J Biol Chem* **278**:45062–45071.
- Hofmann AF (1994) *Bile Acids*. Raven Press, New York.
- Hui DY and Howles PN (2005) Molecular mechanisms of cholesterol absorption and transport in the intestine. *Semin Cell Dev Biol* **16**:183–192.
- Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, et al. (2005) Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. *Cell Metab* **2**:217–225.

- Kessler M, Acuto O, Storelli C, Murer H, Müller M, and Semenza G (1978) A modified procedure for the rapid preparation of efficiently transporting vesicles from small intestinal brush border membranes. Their use in investigating some properties of D-glucose and choline transport systems. *Biochim Biophys Acta* **506**:136–154.
- Kim I, Ahn SH, Inagaki T, Choi M, Ito S, Guo GL, Klierer SA, and Gonzalez FJ (2007) Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. *J Lipid Res* **48**:2664–2672.
- Kitada H, Miyata M, Nakamura T, Tozawa A, Honma W, Shimada M, Nagata K, Sinal CJ, Guo GL, Gonzalez FJ, et al. (2003) Protective role of hydroxysteroid sulfotransferase in lithocholic acid-induced liver toxicity. *J Biol Chem* **278**:17838–17844.
- Kullak-Ublick GA, Stieger B, and Meier PJ (2004) Enterohepatic bile salt transporters in normal physiology and liver disease. *Gastroenterology* **126**:322–342.
- Li H, Chen F, Shang Q, Pan L, Shneider BL, Chiang JY, Forman BM, Ananthanarayanan M, Tint GS, Salen G, et al. (2005) FXR-activating ligands inhibit rabbit ASBT expression via FXR-SHP-FTF cascade. *Am J Physiol Gastrointest Liver Physiol* **288**:G60–G66.
- Li H, Xu G, Shang Q, Pan L, Shefer S, Batta AK, Bollineni J, Tint GS, Keller BT, and Salen G (2004) Inhibition of ileal bile acid transport lowers plasma cholesterol levels by inactivating hepatic farnesoid X receptor and stimulating cholesterol 7 α -hydroxylase. *Metabolism* **53**:927–932.
- Lu TT, Makishima M, Repa JJ, Schoonjans K, Kerr TA, Auwerx J, and Mangelsdorf DJ (2000) Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. *Mol Cell* **6**:507–515.
- Miyata M, Tozawa A, Otsuka H, Nakamura T, Nagata K, Gonzalez FJ, and Yamazoe Y (2005) Role of farnesoid X receptor in the enhancement of canalicular bile acid output and excretion of unconjugated bile acids: a mechanism for protection against cholic acid-induced liver toxicity. *J Pharmacol Exp Ther* **312**:759–766.
- Miyata M, Watase H, Hori W, Shimada M, Nagata K, Gonzalez FJ, and Yamazoe Y (2006) Role for enhanced faecal excretion of bile acid in hydroxysteroid sulfotransferase-mediated protection against lithocholic acid-induced liver toxicity. *Xenobiotica* **36**:631–644.
- Neimark E, Chen F, Li X, and Shneider BL (2004) Bile acid-induced negative feedback regulation of the human ileal bile acid transporter. *Hepatology* **40**:149–156.
- Norlin M and Wikvall K (2007) Enzymes in the conversion of cholesterol into bile acids. *Curr Mol Med* **7**:199–218.
- Pauli-Magnus C and Meier PJ (2006) Hepatobiliary transporters and drug-induced cholestasis. *Hepatology* **44**:778–787.
- Ponz de Leon M, Loria P, Iori R, and Carulli N (1981) Cholesterol absorption in cirrhosis: the role of total and individual bile acid pool size. *Gastroenterology* **80**:1428–1437.
- Rao A, Haywood J, Craddock AL, Belinsky MG, Kruh GD, and Dawson PA (2008) The organic solute transporter α - β , Osta-Ost β , is essential for intestinal bile acid transport and homeostasis. *Proc Natl Acad Sci U S A* **105**:3891–3896.
- Russell DW (2003) The enzymes, regulation, and genetics of bile acid synthesis. *Annu Rev Biochem* **72**:137–174.
- Schwarz M, Russell DW, Dietschy JM, and Turley SD (1998) Marked reduction in bile acid synthesis in cholesterol 7 α -hydroxylase-deficient mice does not lead to diminished tissue cholesterol turnover or to hypercholesterolemia. *J Lipid Res* **39**:1833–1843.
- Shneider BL, Dawson PA, Christie DM, Hardikar W, Wong MH, and Suchy FJ (1995) Cloning and molecular characterization of the ontogeny of a rat ileal sodium-dependent bile acid transporter. *J Clin Invest* **95**:745–754.
- Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, and Gonzalez FJ (2000) Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. *Cell* **102**:731–744.
- Sonoda J, Chong LW, Downes M, Barish GD, Coulter S, Liddle C, Lee CH, and Evans RM (2005) Pregnane X receptor prevents hepatorenal toxicity from cholesterol metabolites. *Proc Natl Acad Sci U S A* **102**:2198–2203.
- Suchy FJ and Ananthanarayanan M (2006) Bile salt excretory pump: biology and pathobiology. *J Pediatr Gastroenterol Nutr* **43** (Suppl 1):S10–S16.
- Teng S and Piquette-Miller M (2007) Hepatoprotective role of PXR activation and MRP3 in cholic acid-induced cholestasis. *Br J Pharmacol* **151**:367–376.
- Thomas C, Landrier JF, Gaillard D, Grober J, Monnot MC, Athias A, and Besnard P (2006) Cholesterol dependent downregulation of mouse and human apical sodium dependent bile acid transporter (ASBT) gene expression: molecular mechanism and physiological consequences. *Gut* **55**:1321–1331.
- Tiemann M, Han Z, Soccio R, Bollineni J, Shefer S, Schayek E, and Breslow JL (2004) Cholesterol feeding of mice expressing cholesterol 7 α -hydroxylase increases bile acid pool size despite decreased enzyme activity. *Proc Natl Acad Sci U S A* **101**:1846–1851.
- Trauner M, Wagner M, Fickert P, and Zollner G (2005) Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. *J Clin Gastroenterol* **39**:S111–S124.
- Wong MH, Oelkers P, and Dawson PA (1995) Identification of a mutation in the ileal sodium-dependent bile acid transporter gene that abolishes transport activity. *J Biol Chem* **270**:27228–27234.
- Woollett LA, Buckley DD, Yao L, Jones PJ, Granholm NA, Tolley EA, Tso P, and Heubi JE (2004) Cholic acid supplementation enhances cholesterol absorption in humans. *Gastroenterology* **126**:724–731.
- Woollett LA, Wang Y, Buckley DD, Yao L, Chin S, Granholm N, Jones PJ, Setchell KD, Tso P, and Heubi JE (2006) Micellar solubilisation of cholesterol is essential for absorption in humans. *Gut* **55**:197–204.
- Xia X, Roundtree M, Merikhi A, Lu X, Shentu S, and Lesage G (2004) Degradation of the apical sodium-dependent bile acid transporter by the ubiquitin-proteasome pathway in cholangiocytes. *J Biol Chem* **279**:44931–44937.
- Xu G, Shneider BL, Shefer S, Nguyen LB, Batta AK, Tint GS, Arrese M, Thevananthan S, Ma L, Stengelin S, et al. (2000) Ileal bile acid transport regulates bile acid pool, synthesis, and plasma cholesterol levels differently in cholesterol-fed rats and rabbits. *J Lipid Res* **41**:298–304.

Address correspondence to: Masaaki Miyata, Division of Drug Metabolism and Molecular Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University, 6-3, Aoba, Aramaki, Aoba-ku, Sendai, 980-8578, Japan. E-mail: miyata@mail.pharm.tohoku.ac.jp